# A Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD)

> **NCT07547228** · PHASE1,PHASE2 · RECRUITING · sponsor: **Intra-IMMUSG Pte Ltd** · enrollment: 15 (estimated)

## Conditions studied

- Neovascular Age Related Macular Degeneration

## Interventions

- **BIOLOGICAL:** PRL3-ZUMAB
- **OTHER:** Normal Saline (0.9% Sodium Chloride)

## Key facts

- **NCT ID:** NCT07547228
- **Lead sponsor:** Intra-IMMUSG Pte Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-11
- **Primary completion:** 2027-02-07
- **Final completion:** 2027-07-07
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07547228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07547228, "A Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07547228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*